PDCD1 and neoplasm: In contrast, anti-PD-1 immunotherapy has previously been shown to induce the proliferation of tumor-specific CD8+ T-cells33–35, which leads to increased expression of Ki-67 in immune cells in the tumor micro-environment and peripheral blood.